John D Lambris

25PUBLICATIONS
129CO-AUTHORS
Proteins and peptidesHaematological tumoursMedical devicesBiologically active moleculesCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|May 01, 2026
New Analogs of the Compstatin Family of Clinical Complement Inhibitors with Low Picomolar Target Affinity.

|Dec 12, 2024
The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response.

Yaiza Senent, Ana Remírez, David Repáraz

|Jun 12, 2023
The Complement-Targeted Inhibitor Mini-FH Protects against Experimental Periodontitis via Both C3-Dependent and C3-Independent Mechanisms.

Xiaofei Li, Hui Wang, Christoph Q Schmidt

|Feb 09, 2023
Complement-targeted therapeutics: An emerging field enabled by academic drug discovery.

Christina Lamers, Daniel Ricklin, John D Lambris

|Aug 17, 2022
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.

Panagiotis Skendros, Georgios Germanidis, Dimitrios C Mastellos

|Jul 05, 2022
Considering innate immune responses in SARS-CoV-2 infection and COVID-19.

Michael S Diamond, John D Lambris, Jenny P Ting

Pageof 5

Frequent Collaborators

7 joint publications

Dimitrios C Mastellos

6 joint publications

Daniel Ricklin

4 joint publications

George Hajishengallis

4 joint publications

Anna M Blom